Wednesday July 4, 2018 |
07:30 | Registration |
|
09:00 | Opening and Inaugural Lecture |
|
| Session Chair |
Dr Luc VAN HIJFTE (MERCACHEMSYNCOM, Nijmegen, The Netherlands) |
09:30 | PL01 - Disrupting Cancer Care & Outcomes by Putting Patients in the Driving Seat |
Dr Anne BRUINVELS (PX HEALTHCARE, London, United Kingdom) |
| Session 1 - New Breakthrough in GPCR Structure, Function and Drug Discovery |
|
| Session Chair |
Dr Luc VAN HIJFTE (MERCACHEMSYNCOM, Nijmegen, The Netherlands) |
10:15 | PL02 - Chemogenetic Approachs to Validate Poorly Characterised GPCRS |
Prof. Graeme MILLIGAN (UNIVERSITY OF GLASGOW, Glasgow, United Kingdom) |
11:00 | Coffee break and Exhibition |
|
| Session Chair |
Prof. Dominique BONNET (CNRS-UNIVERSITY OF STRASBOURG, Illkirch, France) |
11:30 | PL03 - Discovery of Balovaptan, a Vasopressin 1a Receptor Antagonist for the Treatment of Autism |
Dr Patrick SCHNIDER (ROCHE PHARMACEUTICAL, Schlieren, Switzerland) |
12:15 | PL04 - Ghrelin Receptor Ligands: from the Bench to the Drug on the Market |
Dr Jean-Alain FEHRENTZ (CNRS-UNIVERSITY OF MONTPELLIER, Montpellier, France) |
13:00 | Lunch |
|
13:30 | Poster session and Exhibition |
|
| Session sponsored by Sanofi |
|
| Session Chair |
Dr Gilbert MARCINIAK (SANOFI, Strasbourg, France) |
15:00 | PL05 - Structure-Based Drug Discovery for G Protein-Coupled Purine Receptors |
Prof. Kenneth A. JACOBSON (NIDDK, Bethesda, United States) |
15:45 | PL06 - Structure-guided Development of Selective GPCR Ligands |
Prof. Peter GMEINER (FRIEDRICH ALEXANDER UNIVERSITY, Erlangen, Germany) |
16:30 | Coffee break and Exhibition |
|
| Session 2 - Novel Synthetic Methods For Therapeutic Innovation (sponsored by the LabEx MEDALIS) |
|
| Session Chair |
Dr Alain WAGNER (CNRS/UNIVERSITY OF STRASBOURG, Illkirch, France) |
17:00 | PL07 - Late Stage Fluorination for Medicine |
Prof. Véronique GOUVERNEUR (UNIVERSITY OF OXFORD, Oxford, United Kingdom) |
17:45 | PL08 - Single Electron Processes Enabling Organic Synthesis |
Prof. Gary A. MOLANDER (UNIVERSITY OF PENNSYLVANIA, Philadelphia, United States) |
18:30 | Welcome and networking reception |
|
Thursday July 5, 2018 |
| Session sponsored by Janssen Research & Development |
|
| Session Chair |
Prof. Sebastien PAPOT (UNIVERSITY OF POITIERS, Poitiers, France) Dr Sandrine GROSSE (JANSSEN, Beerse, Belgium) |
08:30 | PL09 - Paul Ehrlich Award Lecture - Chemical Biology on the Genome |
Prof. Sir Shankar BALASUBRAMANIAN (UNIVERSITY OF CAMBRIDGE, Cambridge, United Kingdom) |
Session 3 - Biologically Active Chemical Space | Session 4 - Chemokine Targeted Drug Discovery |
| Session Chair |
Prof. Sebastien PAPOT (UNIVERSITY OF POITIERS, Poitiers, France) |
|
| Session Chair |
Dr Sébastien ALBRECHT (UNIVERSITY OF HAUTE-ALSACE, Mulhouse, France) |
|
09:30 | PL10 - Ancient and Modern Scaffolds for Biologically Active Chemical Space |
Prof. Arasu GANESAN (UNIVERSITY OF EAST ANGLIA, Norwich, United Kingdom) |
|
| PL11 - Identification of Chemokine Neutraligands Targeting Atopic Diseases and Hyperalgesia |
Dr Jean-Luc GALZI (CNRS-UNIVERSITY OF STRASBOURG, Illkirch, France) |
|
|
10:15 | Coffee break and Exhibition |
|
Session 5 - Advances in GPCR drug discovery | Session 6 - Advances in Biological Imaging |
| Session Chair |
Prof. Marcel HIBERT (UNIVERSITÉ DE STRASBOURG, ILLKIRCH, France) |
|
| Session Chair |
Dr Maria DUCA (UNIVERSITÉ CÔTE D'AZUR, Nice, France) |
|
11:00 | KL01 - Discovery of The Clinical Candidate Ribuvaptan, a Dual Acting Vasopressin V1a/V2 Receptor Antagonist for the Treatment of Heart Failure |
Dr Carsten SCHMECK (BAYER, Wuppertal, Germany) |
|
| KL03 - Dye-loaded Lipid Nanoparticles: Contrast Agents for Image-guided Surgery and Tools for Drug Delivery |
Dr Isabelle TEXIER (LETI-HEALTH, Grenoble, France) |
|
11:30 | KL02 - Discovery of New Brain Penetrating Neuropeptide S Receptor (NPSR) Antagonists |
Dr Julien POTHIER (IDORSIA PHARMACEUTICALS LTD., Allschwil, Switzerland) |
|
|
|
12:00 | Lunch |
|
12:30 | Poster session and Exhibition |
|
13:00 | Career Session |
|
Session 7 - Challenging Targets and Approaches (sponsored by Institut de Recherche Servier) | Session 8 - Understanding Binding Characteristics |
| Session Chair |
Dr Arnaud LE TIRAN (INSTITUT DE RECHERCHES SERVIER, Croissy sur Seine, France) |
|
| Session Chair |
Prof. Didier ROGNAN (CNRS/UNIVERSITY OF STRASBOURG, Illkirch, France) |
|
|
| PL14 - Pharmacophore-based Analysis of Molecular Dynamics Trajectories: Towards Understanding KD of Protein Ligands |
Prof. Thierry LANGER (UNIVERSITY OF VIENNA, Vienna, Austria) |
|
14:45 | PL13 - Potential Therapeutic Targets in the Brain Renin-Agiotensin and Apelinergic Systems for Treatment of Cardiovascular Diseases |
Dr Catherine LLORENS-CORTES (INSERM/COLLÈGE DE FRANCE, Paris, France) |
|
| PL15 - Identifying Inter-Helical Interactions Involved in GPCR Structure-Function and the Forces that Determine Receptor-Ligand Residence Time |
Dr Alexander HEIFETZ (EVOTEC, Abingdon, United Kingdom) |
|
15:30 | KL05 - Topical Intestinal Agonists of the Bile Acid Receptor TGR5: Controlling Target Engagement by Innovative Molecular Engineering |
Dr Julie CHARTON (UNIVERSITY OF LILLE, INSTITUT PASTEUR DE LILLE, Lille, France) |
|
| KL06 - Drug-target Residence Time – a Misleading Concept |
Dr Rutger FOLMER (SYMERES, Nijmegen, The Netherlands) |
|
|
16:00 | Coffee break and Exhibition |
|
Session 9 - Tackling Challenges in Drug Delivery | Session 10 - Chemistry Driven Biological Exploration |
| Session Chair |
Prof. Line BOUREL (FACULTÉ DE PHARMACIE, ILLKIRCH, France) |
|
| Session Chair |
Prof. Stefan LAUFER (UNIVERSITY OF TÜBINGEN, Tübingen, Germany) |
|
16:30 | PL16 - Cellular Delivery and Oral Uptake of Cyclic Peptides |
Dr Thomas VORHERR (NOVARTIS, Basel, Switzerland) |
|
| PL18 - Chemistry as the Helping Tool to Develop New Therapeutic Strategies |
Prof. Maria Luz LOPEZ RODRIGUEZ (COMPLUTENSE UNIVERSITY OF MADRID, Madrid, Spain) |
|
17:15 | PL17 - Nanoparticle-based Strategies in Oncology |
Prof. Jean-Pierre BENOIT (UNIVERSITY OF ANGERS, Angers, France) |
|
| PL19 - Chemical Tools to Probe Reversible Lysine Acetylation |
Prof. Manfred JUNG (ALBERT LUDWIGS UNIVERSITY OF FREIBURG, Freiburg, Germany) |
|
|
20:00 | Banquet |
|
Friday July 6, 2018 |
| Session 11 - New modalities in Drug Discovery (sponsored by Institut de Recherche Pierre Fabre) |
|
| Session Chair |
Dr Pascal GEORGE (SCT & INDEPENDENT SCIENTIFIC EXPERT & ADVISER, Longvilliers, France) Mr Philippe SCHAMBEL (INSTITUT DE RECHERCHE PIERRE FABRE, TOULOUSE, France) |
08:30 | PL20 - The Confobody Technology, a New Platform to Enable Fragment Screening on GPCRs |
Dr Christel MENET (CONFO THERAPEUTICS, Brussels, Belgium) |
09:15 | PL21 - Pierre Fabre Award lecture PROTAC-mediated Protein Degradation: A New Therapeutic Modality |
Prof. Craig CREWS (YALE UNIVERSITY, New Haven, CT, United States) |
10:00 | Coffee break and Exhibition |
|
| Session 12 - Chemistry in Living Systems |
|
| Session Chair |
Prof. Rebecca DEPREZ-POULAIN (UNIVERSITY OF LILLE, Lille, France) |
10:30 | PL22 - Two Adventures in Chemical Biology - in vivo Chemistry and Real-time Optical Medical Imaging |
Prof. Mark BRADLEY (UNIVERSITY OF EDINBURGH, Edinburgh, United Kingdom) |
11:15 | PL23 - Therapeutic In Vivo Synthetic Chemistry |
Prof. Nori TANAKA (RIKEN, Saitama, Japan) |
12:00 | Concluding remarks |
Prof. Pascal MARCHAND (UNIVERSITY OF NANTES, Nantes, France) Prof. Sebastien PAPOT (UNIVERSITY OF POITIERS, Poitiers, France) |